Magenta therapeutics to explore strategic alternatives

Cambridge, mass., feb. 02, 2023 (globe newswire) -- magenta therapeutics (nasdaq: mgta), a clinical-stage biotechnology company focused on improving stem cell transplantation, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. magenta has made the determination to halt further development of its programs and conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.
DNTH Ratings Summary
DNTH Quant Ranking